ANTI-PD1 IN COMBINATION WITH AN INHIBITOR OF PCSK9 TO INCREASE MHC CLASS I MOLECULE EXPRESSION ON TUMOR CELLS AS IMMUNOTHERAPY FOR NSCLC

Duke University, Durham NC

Investigators